Moxidectin versus ivermectin mass treatment to control river blindness and other common infections in Angolan villages

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 4, community-level comparison randomizes villages in Andulo and Nharea municipalities (Bié Province, Angola) to receive mass drug administration (MDA) with either moxidectin or ivermectin. Researchers will measure changes in the prevalence and intensity of onchocerciasis (river blindness), soil-transmitted helminths (Ascaris, Trichuris, hookworm), and scabies over time. Parasite genetic testing will be used to estimate impacts on onchocerciasis transmission within communities. Age, pregnancy, breastfeeding, and allergy-based eligibility rules apply and safety and population-level effects will be monitored during follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female children and adults
* Residents in the villages selected for MDA treatment

Exclusion Criteria:

* Arm 1 (ivermectin): children under the age of 5 and/or under 90 cm of height
* Arm 2 (moxidectin): children under the age of 12 years (who will receive ivermectin if they are at least 90 cm in height/5 years of age and above).
* Arm 1 (ivermectin): Women breast-feeding babies under 45 days of age
* Arm 2 (moxidectin): All breastfeeding women (who will be offered ivermectin if their infants is at least 45 days old)
* Know allergy to ivermectin or moxidectin
* Attending other clinical trials during the study
* Pregnant
* Arm 2 (moxidectin): Women planning to become pregnant in the 3 months post-treatment
* Refusal to receive one or both study drugs, i.e. participants in villages allocated to receive moxidectin who refuse to receive moxidectin will be given the option to receive ivermectin; if they refuse to receive both drugs they will be excluded from the MDA altogether
* Has an illness that makes them too sick or weak to get out of bed
* Currently hospitalized

Where it's running

• Villages in Andulo and Nharea Municipalities
  Andulo, Bíe Province, Angola Recruiting

Study contacts

• Principal investigator: Susana V Nery, PhD — Kirby Institute, University of New South Wales, Australia
• Study coordinator: Susana V Nery, PhD
• Email: snery@kirby.unsw.edu.au
• Phone: +61467076047

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Better options for treating lymphatic filariasis and other infections in communities

  This trial tests whether a three-drug regimen (moxidectin, diethylcarbamazine, and albendazole) can clear lymphatic filariasis, scabies, and strongyloidiasis in people in affected communities, compared with the standard regimen (ivermectin, DEC, and albendazole).

  Recruiting Phase 3 Medicines Development for Global Health · Suva · NCT07159373

• Point-of-care testing program for Hepatitis C screening

  This study is testing if quick Hepatitis C tests done during a single visit can help more at-risk adults get diagnosed and start treatment faster.

  Recruiting at 6 sites Kirby Institute · Canberra, Australian Capital Territory and 12 other locations · NCT05713136

• Timing of COVID-19 booster vaccinations for immunosuppressed patients

  This study is testing whether giving COVID-19 booster shots right before or six months after starting immunosuppressive therapy helps people with autoimmune and inflammatory conditions stay protected better.

  Recruiting at 5 sites Phase 3 Kirby Institute · Blacktown, New South Wales and 4 other locations · NCT05415267

• Evaluating point-of-care testing for Hepatitis C in Australia

  This study is testing if quick finger-stick tests for Hepatitis C can help people in high-risk areas in Australia get diagnosed and treated more easily.

  Recruiting at 11 sites Kirby Institute · Sydney, New South Wales and 15 other locations · NCT05248555

• National program for point-of-care testing of Hepatitis C in Australia

  This study is testing if quick finger-stick tests for Hepatitis C can help more people at risk get diagnosed and treated in places like drug clinics and prisons.

  Recruiting at 52 sites Kirby Institute · Canberra, Australian Capital Territory and 68 other locations · NCT05042544

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.